Przejdź do treściGeneral Medical Discoveries · Human study — phase 1/2a
Researchers tested ARO-RAGE, an experimental inhaled siRNA designed to silence RAGE in lung cells, a protein involved in sustaining inflammatory signalling. In this first-in-human study, the treatment was given to healthy volunteers and people with asthma; it reached its pulmonary target and produced marked reductions in soluble RAGE (sRAGE) in the airways and blood. ARO-RAGE was well tolerated in these early cohorts, with no clinically relevant deterioration in chest X-ray findings, pulmonary function tests or systemic inflammatory markers. The delivery approach is of interest because inhaled siRNA may eventually be explored for other inflammatory lung diseases as well. An orthopaedic surgeon reading early research on inflammatory pathways should note that this was a small early-phase study and it was not designed to show improvement in asthma symptoms or fewer exacerbations, so clinical efficacy remains unproven.
Source: O’Carroll M et al. Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial. Nature Medicine. Published online 9 September 2026. DOI: 10.1038/s41591-026-04607-z. PMID 42717034. Checked 15 September 2026. Access: full article on the publisher’s website and PubMed record; no published correction or retraction was identified in the checked records.
← More General Medical Discoveries
Content prepared by: Tomasz Poboży - orthopaedic surgeon.